134 related articles for article (PubMed ID: 26666246)
1. Impaired PLP-dependent metabolism in brain samples from Huntington disease patients and transgenic R6/1 mice.
Sorolla MA; Rodríguez-Colman MJ; Vall-Llaura N; Vived C; Fernández-Nogales M; Lucas JJ; Ferrer I; Cabiscol E
Metab Brain Dis; 2016 Jun; 31(3):579-86. PubMed ID: 26666246
[TBL] [Abstract][Full Text] [Related]
2. Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism.
Sorolla MA; Rodríguez-Colman MJ; Tamarit J; Ortega Z; Lucas JJ; Ferrer I; Ros J; Cabiscol E
Free Radic Biol Med; 2010 Aug; 49(4):612-21. PubMed ID: 20639122
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression.
Petr GT; Schultheis LA; Hussey KC; Sun Y; Dubinsky JM; Aoki C; Rosenberg PA
Eur J Neurosci; 2013 Aug; 38(3):2477-90. PubMed ID: 23586612
[TBL] [Abstract][Full Text] [Related]
4. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
[TBL] [Abstract][Full Text] [Related]
5. Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model.
Choo YS; Mao Z; Johnson GV; Lesort M
Neurosci Lett; 2005 Sep; 386(1):63-8. PubMed ID: 15993538
[TBL] [Abstract][Full Text] [Related]
6. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease.
Simmons DA; Casale M; Alcon B; Pham N; Narayan N; Lynch G
Glia; 2007 Aug; 55(10):1074-84. PubMed ID: 17551926
[TBL] [Abstract][Full Text] [Related]
7. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
8. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
[TBL] [Abstract][Full Text] [Related]
9. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters.
Estrada-Sánchez AM; Montiel T; Segovia J; Massieu L
Neurobiol Dis; 2009 Apr; 34(1):78-86. PubMed ID: 19168136
[TBL] [Abstract][Full Text] [Related]
10. Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease.
Traficante A; Riozzi B; Cannella M; Rampello L; Squitieri F; Battaglia G
Neuroreport; 2007 Dec; 18(18):1997-2000. PubMed ID: 18007201
[TBL] [Abstract][Full Text] [Related]
11. Vitamin B6 Acquisition and Metabolism in
Da'dara AA; Elzoheiry M; El-Beshbishi SN; Skelly PJ
Front Immunol; 2020; 11():622162. PubMed ID: 33613557
[TBL] [Abstract][Full Text] [Related]
12. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow.
Gianfriddo M; Melani A; Turchi D; Giovannini MG; Pedata F
Neurobiol Dis; 2004 Oct; 17(1):77-88. PubMed ID: 15350968
[TBL] [Abstract][Full Text] [Related]
13. Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy.
Tkac I; Dubinsky JM; Keene CD; Gruetter R; Low WC
J Neurochem; 2007 Mar; 100(5):1397-406. PubMed ID: 17217418
[TBL] [Abstract][Full Text] [Related]
14. Oxygen consumption deficit in Huntington disease mouse brain under metabolic stress.
Lou S; Lepak VC; Eberly LE; Roth B; Cui W; Zhu XH; Öz G; Dubinsky JM
Hum Mol Genet; 2016 Jul; 25(13):2813-2826. PubMed ID: 27193167
[TBL] [Abstract][Full Text] [Related]
15. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
[TBL] [Abstract][Full Text] [Related]
16. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
17. Protein expression in the striatum and cortex regions of the brain for a mouse model of Huntington's disease.
Liu X; Miller BR; Rebec GV; Clemmer DE
J Proteome Res; 2007 Aug; 6(8):3134-42. PubMed ID: 17625815
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.
Hsiao HY; Chiu FL; Chen CM; Wu YR; Chen HM; Chen YC; Kuo HC; Chern Y
Hum Mol Genet; 2014 Aug; 23(16):4328-44. PubMed ID: 24698979
[TBL] [Abstract][Full Text] [Related]
19. Oxidative metabolism and Ca2+ handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington's disease.
Hamilton J; Pellman JJ; Brustovetsky T; Harris RA; Brustovetsky N
Hum Mol Genet; 2016 Jul; 25(13):2762-2775. PubMed ID: 27131346
[TBL] [Abstract][Full Text] [Related]
20. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
